Nowe leki przeciwarytmiczne

Piśmiennictwo

Antzelevitch C., Burashnikov A., Sicouri S., Belardinelli L.: Electrophysiologic basis for the antiarrhythmic actions of ranolazine. „Heart Rhythm.”, 2011, 8(8).Burashnikov A., Di Diego J.M., Barajas-Martínez H., Hu D., Cordeiro J.M., Moise N.S., Kornreich B.G., Belardinelli L., Antzelevitch C.: Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. „Circ. Heart Fail.”, 2014, 7(4).Mihos C.G., Krishna R.K., Kherada N., Larrauri-Reyes M., Tolentino A., Santana O.: The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials. „Pharmacol. Res.”, 2015, Nov 4.Antoons G., Oros A., Beekman J.D., Engelen M.A., Houtman M.J., Belardinelli L., Stengl M., Vos M.A.: Late na (+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. „J. Am. Coll. Cardiol.”, 2010, Feb 23; 55(8).Rastogi S., Sharov V.G., Mishra S., Gupta R.C., Blackburn B., Belardinelli L., Stanley W.C., Sabbah H.N.: Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. „Am. J. Physiol. Heart Circ. Physiol.”, 2008, Nov; 295(5).Koncz I., Szél T,, Bitay M,: Electrophysiological effects of ivabradine in dog and human cardiac preparations: potential antiarrhythmic actions. „Eur. J. Pharmacol.”, 2011, Oct 15.Sosunov E.A., Anyukhovsky E.P.: Differential effects of ivabradine and ryanodine on pacemaker activity in canine sinus node and purkinje fibers. „J. Cardiovasc. Electrophysiol.”, 2012, Jun; 23(6).Cober R.E., Schober K.E., Buffington T.C., Li X., Riesen S.C., Bonagura J.D.: Pharmacodynamic effects of ivabradine, a negative chronotropic agent, in healthy cats. „J. Vet. Cardiol.”, 2011, Dec; 13(4).Riesen S.C., Schober K.E., Smith D.N., Otoni C.C., Li X., Bonagura J.D.: Effects of ivabradine on heart rate and left ventricular function in healthy cats and cats with hyp...